Schering-Plough
Executive Summary
Obtains worldwide rights to the anticancer drug temozolomide from Cancer Research Campaign Technology Ltd., the commercial branch of the United Kingdom's Cancer Research Campaign. Temozolomide is under study for the treatment of gliomas, or brain tumors. Schering will pay licensing fees, milestone payments and royalties to CRCT and will be responsible for pre-clinical testing and clinical development. Schering characrterized the deal in a June 26 release as a "multi-million-dollar agreement".